Literature DB >> 9299600

Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism.

D R Umbenhauer1, G R Lankas, T R Pippert, L D Wise, M E Cartwright, S J Hall, C M Beare.   

Abstract

There is a subpopulation of the CF-1 mouse strain that is very sensitive to the neurotoxicity induced by the avermectins, a class of natural products widely used in veterinary and human medicine as anti-parasitic agents. This sensitivity results from a lack of P-glycoprotein in the intestine and brain of sensitive animals, allowing increased penetration of these compounds in the blood and brain, respectively. We describe a restriction fragment length polymorphism that is able to predict which animals will be deficient in this protein, confirming at the genetic level a heterogeneous population of this mouse strain. Breeding studies demonstrated that the inheritance of the markers follows a normal Mendelian autosomal pattern. Sensitive "-/-" animals are deficient in P-glycoprotein in those tissues known to express primarily mdr1a, but have normal P-glycoprotein levels in tissues known to express primarily mdr1b or mdr2, suggesting that the defect in the sensitive animals is limited to the mdr1a gene. The P-glycoprotein expression in the brain is dependent on the genotype, which also determines the susceptibility to the avermectin-induced neurotoxicity, with the "-/-" animals being most sensitive, and the "+/-" animals having less P-glycoprotein and therefore increased CNS sensitivity compared to the "+/+" animals. The ability to segregate this strain into -/- and +/+ animals may prove useful for examining the physiological role of P-glycoprotein in drug absorption and distribution and related toxicity. These data also provide a warning that experiments carried out with P-glycoprotein substrates in the heterogeneous population of the CF-1 mouse must be interpreted with caution. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299600     DOI: 10.1006/taap.1997.8225

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  24 in total

Review 1.  The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

Authors:  Mandy Juarez; Alejandro Schcolnik-Cabrera; Alfonso Dueñas-Gonzalez
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

Review 2.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

4.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

5.  Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.

Authors:  Grégoire Dirson; Christine Fernandez; Patrick Hindlet; Françoise Roux; Michèle German-Fattal; François Gimenez; Robert Farinotti
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 6.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

7.  Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.

Authors:  C Dagenais; J Zong; J Ducharme; G M Pollack
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

Review 8.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

9.  Moxidectin toxicity in senescence-accelerated prone and resistant mice.

Authors:  Vanessa K Lee; Asheesh K Tiwary; Prachi Sharma-Reddy; Karen A Lieber; Douglas K Taylor; Deborah M Mook
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

10.  Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.

Authors:  Suneet Shukla; Hani Zaher; Anika Hartz; Björn Bauer; Joseph A Ware; Suresh V Ambudkar
Journal:  Pharm Res       Date:  2008-10-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.